Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 41

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 4
Chunk 41
---

Item 4.   Information on the Company
------------------------------------

A.   History and development of the Company
-------------------------------------------
<{self.tag} alt="{self.alt}" src="{self.src}"> 
The Company was incorporated on September 12, 1990 under the Canada Business Corporations Act (the “CBCA”) and continues to be governed by the CBCA. Our registered address is located at 222 Bay St., Suite 3000, Toronto, Ontario, Canada M5K 1E7 c/o Norton Rose Fulbright Canada LLP and we operate another office located at 315 Sigma Drive, Summerville, South Carolina 29486; our telephone number is (843) 900-3223 and our website is www.cosciensbio.com/.
 
In May 2004, we changed our name to Aeterna Zentaris Inc. On May 3, 2024, we completed a 4-for-1 share consolidation (reverse stock split) and previously, on July 18, 2022, we completed a 25-for-1 share consolidation and on November 17, 2015, we completed 100-to-1 share consolidation (reverse stock split).
 
Our Common Shares commenced trading on a consolidated and adjusted basis on both the NASDAQ and the TSX on November 20, 2015 under the trading symbol “AEZS”. Our Common Shares have been listed for trading on both the NASDAQ and the TSX under the trading symbol “CSCI” since August 9, 2024.
 
Plan of arrangement
 
On June 3, 2024, Aeterna Zentaris Inc. (“Aeterna”) and Ceapro Inc. (“Ceapro”) closed their all-stock merger of equals transaction pursuant to a Plan of Arrangement (the “Transaction”). The Transaction was completed by way of court approved plan of arrangement pursuant to the terms of an arrangement agreement entered into by Aeterna and Ceapro on December 14, 2023. As a result of the Transaction, each outstanding Ceapro common share was exchanged for 0.02360 of an Aeterna common share. Additionally, as part of the Transaction, Aeterna issued to its shareholders immediately prior to the closing of the Transaction, 0.47698 of a share purchase warrant (a “New Warrant”) for each Aeterna common share or warrant held.
 
Following the closing of the Transaction, former shareholders of Ceapro owned approximately 50%